382185
HDAC Inhibitor XXII, NCH51
The HDAC Inhibitor XXII, NCH51, also referenced under CAS 848354-66-5, controls the biological activity of HDAC. This small molecule/inhibitor is primarily used for Cell Structure applications.
别名:
HDAC Inhibitor XXII, NCH51, Thioisobutyric acid(S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
登录查看公司和协议定价
所有图片(1)
About This Item
质量水平
方案
≥97% (HPLC)
表单
powder
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
颜色
white
溶解性
DMSO: 100 mg/mL
运输
ambient
储存温度
−20°C
InChI
1S/C20H26N2O2S2/c1-15(2)19(24)25-13-9-4-3-8-12-18(23)22-20-21-17(14-26-20)16-10-6-5-7-11-16/h5-7,10-11,14-15H,3-4,8-9,12-13H2,1-2H3,(H,21,22,23)
InChI key
MDYDGUOQFUQOGE-UHFFFAOYSA-N
一般描述
A cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA′s hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
A cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA′s hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
警告
Toxicity: Regulatory Review (Z)
重悬
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
Sanda, T., et al. 2007. Leukemia21, 2344.
Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett.17, 1558.
Suzuki, T., et al. 2005. J. Med. Chem.48, 1019.
Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett.17, 1558.
Suzuki, T., et al. 2005. J. Med. Chem.48, 1019.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Minghui Wang et al.
Neuron, 109(2), 257-272 (2020-11-26)
To identify the molecular mechanisms and novel therapeutic targets of late-onset Alzheimer's Disease (LOAD), we performed an integrative network analysis of multi-omics profiling of four cortical areas across 364 donors with varying cognitive and neuropathological phenotypes. Our analyses revealed thousands
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门